Payment overview · 2025
General Payments
$37.42
2 reported records · 2 companies
Healthcare provider profile · identity verified
Mohit Singh Negi, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MILLERSVILLE, MD · NPI 1346285061
Verified facts
What the public records show
CMS Open Payments records show Mohit Singh Negi, M.D. received $37.42 in general payments during 2025 across 2 reported records.
GlaxoSmithKline, LLC. accounted for 53.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 237 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.84 | 53.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.58 | 47.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $37.42 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.84 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.84 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.58 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.58 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
237 | 48 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 644 | 166 |
| Amlodipine Besylate | Amlodipine Besylate | 437 | 112 |
| Losartan Potassium | Losartan Potassium | 432 | 113 |
| Levothyroxine Sodium | Levothyroxine Sodium | 364 | 86 |
| Furosemide | Furosemide | 357 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 326 | 86 |
| Lisinopril | Lisinopril | 262 | 64 |
| Omeprazole | Omeprazole | 240 | 58 |
| Eliquis | Apixaban | 237 | 48 |
| Gabapentin | Gabapentin | 219 | 64 |
| Metoprolol Tartrate | Metoprolol Tartrate | 212 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 201 | 53 |
| Donepezil Hcl | Donepezil Hcl | 194 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 186 | 55 |
| Duloxetine Hcl | Duloxetine Hcl | 184 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 172 | 47 |
| Sertraline Hcl | Sertraline Hcl | 138 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 128 | 39 |
| Potassium Chloride | Potassium Chloride | 127 | 34 |
| Allopurinol | Allopurinol | 123 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 121 | 28 |
| Metformin Hcl | Metformin Hcl | 117 | 39 |
| Simvastatin | Simvastatin | 116 | 35 |
| Trazodone Hcl | Trazodone Hcl | 114 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 100 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 100 | 51 |
| Alendronate Sodium | Alendronate Sodium | 95 | 23 |
| Tramadol Hcl | Tramadol Hcl | 94 | 21 |
| Famotidine | Famotidine | 90 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 83 | 23 |
| Mirtazapine | Mirtazapine | 80 | 24 |
| Buspirone Hcl | Buspirone Hcl | 77 | 21 |
| Celecoxib | Celecoxib | 77 | 24 |
| Finasteride | Finasteride | 71 | 17 |
| Carvedilol | Carvedilol | 69 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 67 | 15 |
| Montelukast Sodium | Montelukast Sodium | 65 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 65 | 15 |
| Alprazolam | Alprazolam | 63 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 59 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 58 | 22 |
| Gemtesa | Vibegron | 58 | 17 |
| Ezetimibe | Ezetimibe | 57 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 57 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 11 |
| Ozempic | Semaglutide | 54 | 12 |
| Xarelto | Rivaroxaban | 54 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 53 | 23 |
| Nystatin | Nystatin | 52 | 24 |
| Olanzapine | Olanzapine | 52 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 52 | suppressed |
| Bupropion Xl | Bupropion Hcl | 50 | 21 |
| Meloxicam | Meloxicam | 49 | 19 |
| Glipizide Er | Glipizide | 45 | 11 |
| Lovastatin | Lovastatin | 44 | suppressed |
| Myrbetriq | Mirabegron | 44 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 43 | 20 |
| Spironolactone | Spironolactone | 43 | 16 |
| Farxiga | Dapagliflozin Propanediol | 42 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 42 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | suppressed |
| Januvia | Sitagliptin Phosphate | 40 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 29 |
| Lorazepam | Lorazepam | 39 | 17 |
| Prednisone | Prednisone | 39 | 28 |
| Valsartan | Valsartan | 39 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 38 | 11 |
| Digoxin | Digoxin | 35 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 35 | suppressed |
| Memantine Hcl | Memantine Hcl | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Ibuprofen | Ibuprofen | 34 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 33 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Pregabalin | Pregabalin | 31 | suppressed |
| Latanoprost | Latanoprost | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 22 |
| Atenolol | Atenolol | 27 | 13 |
| Azithromycin | Azithromycin | 27 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Mupirocin | Mupirocin | 25 | 23 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 20 | 13 |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 16 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 16 | suppressed |
| Zolmitriptan | Zolmitriptan | 16 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Clozapine | Clozapine | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Praluent Pen | Alirocumab | 14 | suppressed |
| Propylthiouracil | Propylthiouracil | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 11 | suppressed |
| Dofetilide | Dofetilide | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $37.42 · 2 records | GlaxoSmithKline, LLC. | ABRYSVO, AREXVY, COMIRNATY, PREVNAR 20, SHINGRIX | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error